StephenJNogaMDPh.D.

Hematologic Oncology

Medical Oncologist

Dr. Noga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Stephen Noga is a specialist in oncology, with a subspecialty in hematologic oncology, based in Catonsville MD. He is currently the Medical Director for MRD and Exact Sciences and the Oncology Advisor for Immunocine Dendritic Cell Therapy. He completed his education, residency in Internal Medicine, and a fellowship in Hematology and Medical Oncology at Johns Hopkins University School of Medicine. Dr. Noga's expertise includes the treatment of conditions such as amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and multiple myeloma. He has published several studies in respected journals and has been cited multiple times. He has also contributed to clinical trials, such as a dose study of Doxil. Among his recognitions, he received the CMS Meaningful Use Stage 1 Certification from ARIA Medical Oncology EMR, Varian Medical Systems in 2012.

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1990 - 1992
Johns Hopkins UniversityResidency, Internal Medicine, 1987 - 1990
Johns Hopkins University School of MedicineClass of 1987

CMS Meaningful Use Stage 1 Certification ARIA Medical Oncology EMR, Varian Medical Systems, 2012

PubMed

2 citations
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.
Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati
Blood Cancer Journal. 2023-09-19
10 citations
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Sudhir Manda, Habte A. Yimer, Stephen J. Noga, Saulius Girnius, Christopher A. Yasenchak
Clinical Lymphoma, Myeloma & Leukemia. 2020-11-01
2 citations
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup ...
Cindy Weinstein, Karin Jordan, Stuart A. Green, S. Khanani, Elizabeth Beckford-Brathwaite
BMC Cancer. 2020-09-25

Abstracts/Posters

Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...
Stephen J Noga, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Isct 9th Annual Meeting: Isct 2003National Cancer Institute2003
Core--Hematopoietic And Therapeutic Support FacilityNational Cancer Institute2001–2002
Core--Hematopoietic &Therapeutic Support ServiceNational Cancer Institute2001–2002
Core--Graft Engineering LaboratoryNational Cancer Institute1996–2000
Core--Graft Engineering FacilityNational Cancer Institute1996–2000
Engineering Alternative Donor Grafts To Improve SurvivalNational Cancer Institute1995–1998